Intravitreal bevacizumab for retinal vein occlusion and early growth of epiretinal membrane: A possible secondary effect?

British Journal of Ophthalmology

Volumn 95, Issue 3, 2011, Pages 391-395

  Marticorena, Joaquin ^a   Romano, Mario R ^b   Heimann, Heinrich ^b   Stappler, Theodore ^b   Gibran, Kurshid ^c   Groenewald, Carl ^b   Pearce, Ian ^b   Wong, David ^d  

^a HOSPITAL DE L ESPERANÇA   (Spain)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^c University of Texas Medical Branch School of Medicine   (United States)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; TRIAMCINOLONE;

ANEURYSM; ARTICLE; BLEEDING; BLURRED VISION; CASE STUDY; CATARACT; CEREBROVASCULAR ACCIDENT; COCHRANE LIBRARY; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CORNEA DISEASE; DRUG FATALITY; DRUG MONITORING; DRUG SAFETY; DUODENAL ULCER BLEEDING; EMBASE; ENDOPHTHALMITIS; EYE INFLAMMATION; EYE INJURY; EYE PAIN; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; HYPERTENSION; ILIAC ARTERY ANEURYSM; INTRAOCULAR HYPERTENSION; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; LENS DISEASE; MEDLINE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELIABILITY; RETINA DETACHMENT; RETINA INJURY; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA HEMORRHAGE; RETINA PIGMENT EPITHELIOPATHY; RETINA TEAR; SAMPLE SIZE; SIDE EFFECT; SINGLE DRUG DOSE; STROKE; SUBDURAL HEMATOMA; SUBRETINAL NEOVASCULARIZATION; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TRANSIENT CORNEAL EPITHELIOPATHY; TRAUMATIC LENS DAMAGE; UNSPECIFIED SIDE EFFECT; UVEITIS; VITREOUS BODY DETACHMENT; VITREOUS HEMORRHAGE;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DRUG ADMINISTRATION SCHEDULE; EPIRETINAL MEMBRANE; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 79952033566     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.177287     Document Type: Article

References (25)

1. Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 2002;120:1644-50. (Pubitemid 36401798)
2. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336-9. (Pubitemid 41073113)
3. Kreutzer TC, Alge CS, Wolf AH, et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 2008;92:351-5. (Pubitemid 351363529)
4. Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (avastin) for macular oedema secondary to retinal vein occlusion: 12-Month results of a prospective clinical trial. Br J Ophthalmol 2009;93:452-6.
5. Wu L, Arevalo JF, Berrocal MH, et al. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months. Retina 2009;29:1396-403.
6. Spaide RF, Chang LK, Klancnik JM, et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009;147:298-306.
7. Matsumoto Y, Freund KB, Peiretti E, et al. Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina 2007;27:426-31. (Pubitemid 46624281)
8. Kim KS, Chang HR, Song S. Ischaemic change after intravitreal bevacizumab (Avastin) injection for macular oedema secondary to non-ischaemic central retinal vein occlusion. Acta Ophthalmol 2008;86:925-7.
9. Mitchell P, Smith W, Chey T, et al. Prevalence and associations of epiretinal membranes. The blue mountains eye study, australia. Ophthalmology 1997;104:1033-40.
10. Wise GN. Macular changes after venous obstruction. Arch Ophthalmol 1957;58:544-57.
11. Hood JD, Meininger CJ, Ziche M, et al. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998;274:1054-8.
12. Namba T, Koike H, Murakami K, et al. Angiogenesis induced by endothelial nitric oxide synthase gene through vascular endothelial growth factor expression in a rat hindlimb ischemia model. Circulation 2003;108:2250-7. (Pubitemid 37363043)
13. Yuan Y, Granger HJ, Zawieja DC, et al. Histamine increases venular permeability via a phospholipase C-NO synthase-guanylate cyclase cascade. Am J Physiol 1993;264:1734-9.
14. Ziche M, Morbidelli L, Masini E, et al. Nitric oxide promotes DNA synthesis and cyclic GMP formation in endothelial cells from postcapillary venules. Biochem Biophys Res Commun 1993;192:1198-203. (Pubitemid 23218541)
15. Ziche M, Parenti A, Ledda F, et al. Nitric oxide promotes proliferation and plasminogen activator production by coronary venular endothelium through endogenous bFGF. Circ Res 1997;80:845-52. (Pubitemid 27230059)
16. Donati G, Pournaras CJ, Pizzolato GP, et al. Decreased nitric oxide production accounts for secondary arteriolar constriction after retinal branch vein occlusion. Invest Ophthalmol Vis Sci 1997;38:1450-7. (Pubitemid 27278565)
17. Campochiaro PA, Hackett SF, Vinores SA, et al. Platelet-derived growth factor is an autocrine growth stimulator in retinal pigmented epithelial cells. J Cell Sci 1994;107:2459-69. (Pubitemid 24292494)
18. Chen YS, Hackett SF, Schoenfeld CL, et al. Localisation of vascular endothelial growth factor and its receptors to cells of vascular and avascular epiretinal membranes. Br J Ophthalmol 1997;81:919-26. (Pubitemid 27469979)
19. Gardiner TA, Gibson DS, de Gooyer TE, et al. Inhibition of tumor necrosis factor-alpha improves physiological angiogenesis and reduces pathological neovascularization in ischemic retinopathy. Am J Pathol 2005;166:637-44. (Pubitemid 40189058)
20. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7. (Pubitemid 24356306)
21. Lange J, Yafai Y, Reichenbach A, et al. Regulation of pigment epithelium-derived factor production and release by retinal glial (Müller) cells under hypoxia. Invest Ophthalmol Vis Sci 2008;49:5161-7.
22. Cosgrove GP, Brown KK, Schiemann WP, et al. Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med 2004;170:242-51. (Pubitemid 38971408)
23. Behzadian MA, Wang XL, Al-Shabrawey M, et al. Effects of hypoxia on glial cell expression of angiogenesis-regulating factors VEGF and TGF-b. Glia 1998;24:216-25. (Pubitemid 28403999)
24. He S, Chen Y, Khankan R, et al. Connective tissue growth factor as a mediator of intraocular fibrosis. Invest Ophthalmol Vis Sci 2008;49:4078-88.
25. Szeto CC, Lai KB, Chow KM, et al. Differential effects of transforming growth factor-beta on the synthesis of connective tissue growth factor and vascular endothelial growth factor by peritoneal mesothelial cell. Nephron Exp Nephrol 2005;99:e95-104.